Anebulo Pharmaceuticals (ANEB) Competitors $1.31 +0.01 (+0.77%) (As of 12/17/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends ANEB vs. ATOS, APLT, ENTA, VXRT, CABA, NLTX, PLX, SAVA, IVA, and EDITShould you be buying Anebulo Pharmaceuticals stock or one of its competitors? The main competitors of Anebulo Pharmaceuticals include Atossa Therapeutics (ATOS), Applied Therapeutics (APLT), Enanta Pharmaceuticals (ENTA), Vaxart (VXRT), Cabaletta Bio (CABA), Neoleukin Therapeutics (NLTX), Protalix BioTherapeutics (PLX), Cassava Sciences (SAVA), Inventiva (IVA), and Editas Medicine (EDIT). These companies are all part of the "pharmaceutical products" industry. Anebulo Pharmaceuticals vs. Atossa Therapeutics Applied Therapeutics Enanta Pharmaceuticals Vaxart Cabaletta Bio Neoleukin Therapeutics Protalix BioTherapeutics Cassava Sciences Inventiva Editas Medicine Anebulo Pharmaceuticals (NASDAQ:ANEB) and Atossa Therapeutics (NASDAQ:ATOS) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, risk, media sentiment, analyst recommendations, profitability, earnings, dividends, valuation and community ranking. Does the MarketBeat Community prefer ANEB or ATOS? Atossa Therapeutics received 230 more outperform votes than Anebulo Pharmaceuticals when rated by MarketBeat users. However, 90.00% of users gave Anebulo Pharmaceuticals an outperform vote while only 65.12% of users gave Atossa Therapeutics an outperform vote. CompanyUnderperformOutperformAnebulo PharmaceuticalsOutperform Votes990.00% Underperform Votes110.00%Atossa TherapeuticsOutperform Votes23965.12% Underperform Votes12834.88% Which has better earnings & valuation, ANEB or ATOS? Atossa Therapeutics is trading at a lower price-to-earnings ratio than Anebulo Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAnebulo PharmaceuticalsN/AN/A-$8.20M-$0.30-4.37Atossa TherapeuticsN/AN/A-$30.09M-$0.22-4.73 Is ANEB or ATOS more profitable? Atossa Therapeutics' return on equity of -35.74% beat Anebulo Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Anebulo PharmaceuticalsN/A -184.40% -158.14% Atossa Therapeutics N/A -35.74%-33.51% Do insiders and institutionals hold more shares of ANEB or ATOS? 28.4% of Anebulo Pharmaceuticals shares are owned by institutional investors. Comparatively, 12.7% of Atossa Therapeutics shares are owned by institutional investors. 85.9% of Anebulo Pharmaceuticals shares are owned by insiders. Comparatively, 7.6% of Atossa Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. Which has more volatility and risk, ANEB or ATOS? Anebulo Pharmaceuticals has a beta of -1.09, indicating that its stock price is 209% less volatile than the S&P 500. Comparatively, Atossa Therapeutics has a beta of 1.21, indicating that its stock price is 21% more volatile than the S&P 500. Does the media refer more to ANEB or ATOS? In the previous week, Atossa Therapeutics had 10 more articles in the media than Anebulo Pharmaceuticals. MarketBeat recorded 10 mentions for Atossa Therapeutics and 0 mentions for Anebulo Pharmaceuticals. Anebulo Pharmaceuticals' average media sentiment score of 1.87 beat Atossa Therapeutics' score of 0.50 indicating that Anebulo Pharmaceuticals is being referred to more favorably in the media. Company Overall Sentiment Anebulo Pharmaceuticals Very Positive Atossa Therapeutics Positive Do analysts prefer ANEB or ATOS? Anebulo Pharmaceuticals currently has a consensus price target of $8.00, indicating a potential upside of 510.69%. Atossa Therapeutics has a consensus price target of $7.00, indicating a potential upside of 573.08%. Given Atossa Therapeutics' higher probable upside, analysts clearly believe Atossa Therapeutics is more favorable than Anebulo Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Anebulo Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Atossa Therapeutics 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummaryAtossa Therapeutics beats Anebulo Pharmaceuticals on 8 of the 14 factors compared between the two stocks. Ad Brownstone ResearchMedia Humiliated: Demo of Elon’s Tech Proves They’re WrongElon Musk believes his new AI product will be worth an incredible $9 trillion. But the mainstream media is not buying it.Click here to watch this demo and decide for yourself. Get Anebulo Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ANEB and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ANEB vs. The Competition Export to ExcelMetricAnebulo PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$33.97M$6.87B$5.19B$9.32BDividend YieldN/A3.06%4.78%4.06%P/E Ratio-4.3710.75128.2217.54Price / SalesN/A288.101,259.00139.66Price / CashN/A56.6541.2237.95Price / Book8.735.394.884.92Net Income-$8.20M$152.04M$119.69M$225.78M7 Day Performance-3.68%-4.33%16.64%-1.56%1 Month Performance-14.38%2.79%16.32%6.68%1 Year Performance-36.10%17.30%35.37%22.48% Anebulo Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ANEBAnebulo Pharmaceuticals2.7501 of 5 stars$1.31+0.8%$8.00+510.7%-33.2%$33.97MN/A-4.374Positive NewsGap DownATOSAtossa Therapeutics1.5805 of 5 stars$1.07-4.5%$7.00+554.2%+40.4%$134.61MN/A-5.208Short Interest ↓APLTApplied Therapeutics4.5136 of 5 stars$1.15flat$6.60+473.9%-62.8%$133.81M$9.99M-0.7130News CoverageGap DownENTAEnanta Pharmaceuticals4.2251 of 5 stars$6.31+4.6%$19.50+209.0%-34.4%$133.73M$67.64M-1.10145High Trading VolumeVXRTVaxart2.367 of 5 stars$0.58-1.2%$3.00+412.9%-6.7%$133.05M$20.14M-1.44109Positive NewsGap DownCABACabaletta Bio2.888 of 5 stars$2.71-3.9%$26.25+868.6%-86.6%$132.46MN/A-1.3150NLTXNeoleukin TherapeuticsN/A$13.96+1.5%N/A+82.6%$131.20MN/A-7.5690PLXProtalix BioTherapeuticsN/A$1.75-2.8%N/A+0.9%$128.85M$65.49M-13.81200Gap UpSAVACassava Sciences4.5587 of 5 stars$2.66-3.3%$111.50+4,091.7%-87.9%$127.97MN/A-1.9930News CoverageIVAInventiva3.2596 of 5 stars$2.39-2.4%$13.25+454.4%-45.2%$125.42M$15.62M0.00100EDITEditas Medicine4.425 of 5 stars$1.48+2.8%$7.00+373.0%-86.1%$122.17M$61.76M-0.61230Analyst ForecastNews CoverageHigh Trading Volume Related Companies and Tools Related Companies Atossa Therapeutics Alternatives Applied Therapeutics Alternatives Enanta Pharmaceuticals Alternatives Vaxart Alternatives Cabaletta Bio Alternatives Neoleukin Therapeutics Alternatives Protalix BioTherapeutics Alternatives Cassava Sciences Alternatives Inventiva Alternatives Editas Medicine Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:ANEB) was last updated on 12/18/2024 by MarketBeat.com Staff From Our PartnersThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredHow this >10-cent coin is going to outperform Bitcoin Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredDo this Before Elon’s Reveal on January 22ndElon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but...Brownstone Research | SponsoredTrump’s Secret Manhattan ProjectOn January 20, a whole new Manhattan Project is set to begin: Trump’s Manhattan Project. Folks, I just s...Banyan Hill Publishing | SponsoredSeeing is believing… Today, I want to share all the details with you… and show you how to leverage this incredible wealth-building ...Porter & Company | SponsoredUncover the Top Gold Stock of the Bull MarketGold Stocks Are Surging—Is West Red Lake Gold Mines Your Next Profit Play?Huge Alerts | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowIt’s here. This is the moment we’ve been waiting for. The next 3-6 months in crypto will be absolutely life...Crypto Swap Profits | SponsoredPlease don’t take this warning lightly…Something huge is about to hit the stock market. Wall St. legend Louis Navellier calls it: "The most signif...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Anebulo Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Anebulo Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
